Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

A Novel Digital Music-based Autonomous Personalized Walking Intervention to Improve Gait and Walking Automaticity in Parkinson Disease (MyMusiQ)

13. července 2026 aktualizováno: Boston University Charles River Campus
The purpose of this research study is to examine the effects of a 3-month personalized community-based walking program called MyMusiQ. The study uses music cues delivered through a digital device in people with Parkinson disease (PD). The investigators want to know if personalized music cueing through the digital device can improve walking quality, walking ability, daily walking amount and intensity, and quality of life, while helping walking feel more automatic and require less mental effort. Participants will take part in this research study for approximately 18 weeks in total. During this time, participants will complete 4 study visits at designated research centers at Boston University, Washington University in St. Louis, or the University of Utah, depending on the site of enrollment.

Přehled studie

Postavení

Zatím nenabíráme

Podmínky

Intervence / Léčba

Detailní popis

The overall goal of this 3-month single-arm multi-center repeated baselines study (N=162) is to examine the effects of a personalized closed-loop music-based digital gait intervention on improving gait quality, capacity, real-world walking performance, and gait automaticity in Parkinson disease (PD). This study builds on a stepwise investigation beginning with a proof-of-concept feasibility study (N=23) followed by a 6-week randomized controlled trial (RCT; N=44). This mechanistic-focused study will examine the substrates of a personalized approach that underlie changes in walking outcomes, as well as identify determinants that determine responsiveness to the intervention. This study is a critical next step to elucidate mechanistic understanding of closed-loop personalized gait approaches and to determine those with PD who benefit most.

The main aims of this mechanistic study seek to examine whether a personalized closed-loop gait intervention improves gait quality, walking capacity, and real-world walking performance beyond baseline variability, and to assess how personalized features influence targeted gait outcomes (Aim 1). Additionally, this study will investigate the effects of the intervention on improving gait automaticity (Aim 2), and identify baseline determinants that predict responsiveness and durability to the intervention on walking capacity (Aim 3). The investigators hypothesize that the intervention will meaningfully improve gait quality (speed, stride length), walking capacity (6-Minute Walk Test), and real-world walking performance (walking intensity and amount) during cued and uncued walking during and after intervention. Furthermore, they hypothesize improvements in gait automaticity (reduced gait variability, dual-tasking costs) following the intervention, and that individuals with worse baseline cognitive-motor capacities may benefit more.

This study will utilize a digital music device (MedRhythms, Inc., Portland, ME). To examine the effects of the intervention, the investigators will use clinical measures of motor and gait function, and quantified movement data on walking using wearable sensors. This study will be implemented by carrying out the following study visits: (1) Primary screen over the phone, (2) In-Person Screening and Baseline Assessment #1, (3) Baseline Assessment #2 (2-3 weeks after Baseline Assessment #1) (4) Personalized, Closed-Loop Music-Based Gait Intervention (3 months) (5) Post-Intervention Assessment (immediately after the intervention, about 3 months), and (6) Durability / Follow-Up Assessment (about 1 month post-intervention). Altogether, these procedures may take about 4 months.

Typ studie

Intervenční

Zápis (Odhadovaný)

200

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

  • Jméno: Erica Clarke, BS
  • Telefonní číslo: 617-358-6157
  • E-mail: egclarke@bu.edu

Studijní záloha kontaktů

  • Jméno: Franchino Porciuncula, EdD, PT, DScPT
  • Telefonní číslo: 617-353-7571
  • E-mail: fporciun@bu.edu

Studijní místa

  • Spojené státy
    • Massachusetts
      • Boston, Massachusetts, Spojené státy, 02215
        • Boston University Center for Neurorehabilitation
        • Kontakt:
          • Erica Clarke, BS
          • Telefonní číslo: 617-358-6157
          • E-mail: egclarke@bu.edu
        • Vrchní vyšetřovatel:
          • Terry D. Ellis, PhD, PT
    • Missouri
      • St Louis, Missouri, Spojené státy, 63110
        • Washington University School of Medicine
        • Kontakt:
        • Kontakt:
          • Kerri Rawson, PhD, MS
          • Telefonní číslo: 813-468-8900
          • E-mail: rawson@wustl.edu
        • Vrchní vyšetřovatel:
          • Gammon Earhart, PT, PhD
    • Utah
      • Salt Lake City, Utah, Spojené státy, 84108
        • University of Utah
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Lee Dibble, PT, PhD

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

  • Dospělý
  • Starší dospělý

Přijímá zdravé dobrovolníky

Ne

Popis

Inclusion Criteria:

  • Self-report of diagnosis of typical Parkinson disease determined by a medical doctor

    -≥ 40 years of age

  • Community-dwelling (e.g. home, independent living, senior housing)
  • Have stable PD medications for at least two weeks prior to enrollment
  • Modified Hoehn and Yahr stages 1-3 per physical exam by a licensed physical therapist
  • Able to walk independently without physical assistance for at least 10 minutes (assistive devices allowed with reciprocal gait pattern)
  • Willing and able to provide informed consent
  • Provide HIPAA Authorization to allow communication with the primary healthcare provider for communication (as needed) during the study period

Exclusion Criteria:

  • < 40 years of age
  • Diagnosis of atypical Parkinsonism
  • Modified Hoehn and Yahr stages 4-5
  • Significantly disturbing freezing episodes during daily walking based on the New Freezing of Gait Questionnaire (Part III Item 7)
  • Fall frequencies >1x/week on average, over the past month.
  • Currently participating in physical therapy for Parkinson gait rehabilitation
  • Currently performing walking exercise at moderate intensities or higher for at least 30 min. per session ≥ 3x/week
  • Self-reported cardiac problems that interfere with the ability to safely exercise (e.g., congestive heart failure, uncontrolled cardiac arrhythmias, chest pain;
  • Orthopedic problems in the lower extremities or spine that may limit walking distance (e.g., severe arthritis, spinal stenosis, or significant pain)
  • Any other medical conditions that would preclude successful participation as determined by the researcher/ physical therapist
  • Cognitive impairment (i.e., Montreal Cognitive Assessment, MoCA < 21)
  • Unable to walk independently (i.e., without physical assistance) at a comfortable speed ≥ 0.4m/s as measured using the 10-meter Walk Test (10mWT) as examined in Baseline #1
  • Resting tachycardia (> 100 beats/min) or uncontrolled blood pressure (resting systolic BP > 160 mmHg or diastolic BP >100 mmHg)) as measured by the researcher/ physical therapist
  • Unable to independently use the music-based digital therapeutic during training
  • Significant hearing impairment

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: N/A
  • Intervenční model: Přiřazení jedné skupiny
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: MyMusiQ (MMQ) Walking intervention
12-week self-directed, home/community-based walking intervention that leverages the benefits of rhythmic auditory stimulation via a digital music device (MedRhythms, Inc., Portland, ME) in improving walking outcomes in persons with PD.
Přístroj: Digital Music Device (MedRhythms, Inc., Portland, ME)
The digital music device is comprised of foot sensors, a smart phone with pre-installed proprietary software application, and headphones. The device obtains real-time walking data through movement sensors that communicate wirelessly with the smartphone application software. Music cues are tailored to the person's walking pattern, and are transmitted wirelessly to the headphones. Music cues are time-shifted to the user's baseline cadence and adjusted in real-time based on the user's walking performance metrics.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Minutes of Moderate Intensity Walking
Časové okno: Baseline 1
The amount of moderate intensity walking, defined as mean number of minutes per day with >100 steps/min, measured using research-grade wearable sensors.
Baseline 1
Minutes of Moderate Intensity Walking
Časové okno: Baseline 2 (2-3 weeks after Baseline 1)
The amount of moderate intensity walking, defined as mean number of minutes per day with >100 steps/min, measured using research-grade wearable sensors.
Baseline 2 (2-3 weeks after Baseline 1)
Minutes of Moderate Intensity Walking
Časové okno: Immediately after the intervention (about 3 months)
The amount of moderate intensity walking, defined as mean number of minutes per day with >100 steps/min, measured using research-grade wearable sensors.
Immediately after the intervention (about 3 months)
Minutes of Moderate Intensity Walking
Časové okno: Follow-Up (about 1 month post-intervention)
The amount of moderate intensity walking, defined as mean number of minutes per day with >100 steps/min, measured using research-grade wearable sensors.
Follow-Up (about 1 month post-intervention)
Daily Step Counts
Časové okno: Baseline 1
Daily step counts refer to the number of steps taken per day. This will be measured using research-grade activity monitors validated for use in PD.
Baseline 1
Daily Step Counts
Časové okno: Baseline 2 (2-3 weeks after Baseline 1)
Daily step counts refer to the number of steps taken per day. This will be measured using research-grade activity monitors validated for use in PD.
Baseline 2 (2-3 weeks after Baseline 1)
Daily Step Counts
Časové okno: Immediately after the intervention (about 3 months)
Daily step counts refer to the number of steps taken per day. This will be measured using research-grade activity monitors validated for use in PD.
Immediately after the intervention (about 3 months)
Daily Step Counts
Časové okno: Follow-Up (about 1 month post-intervention)
Daily step counts refer to the number of steps taken per day. This will be measured using research-grade activity monitors validated for use in PD.
Follow-Up (about 1 month post-intervention)
6-Minute Walk Test
Časové okno: Baseline 1
This is a test of long-distance walking capacity. The participant will be asked to "cover as much distance as they safely can" for 6 minutes. Total distance (m) is the main metric, with greater distance indicating greater walking capacity.
Baseline 1
6-Minute Walk Test
Časové okno: Baseline 2 (2-3 weeks after Baseline 1)
This is a test of long-distance walking capacity. The participant will be asked to "cover as much distance as they safely can" for 6 minutes. Total distance (m) is the main metric, with greater distance indicating greater walking capacity.
Baseline 2 (2-3 weeks after Baseline 1)
6-Minute Walk Test
Časové okno: Immediately after the intervention (about 3 months)
This is a test of long-distance walking capacity. The participant will be asked to "cover as much distance as they safely can" for 6 minutes. Total distance (m) is the main metric, with greater distance indicating greater walking capacity.
Immediately after the intervention (about 3 months)
6-Minute Walk Test
Časové okno: Follow-Up (about 1 month post-intervention)
This is a test of long-distance walking capacity. The participant will be asked to "cover as much distance as they safely can" for 6 minutes. Total distance (m) is the main metric, with greater distance indicating greater walking capacity.
Follow-Up (about 1 month post-intervention)
Gait Speed
Časové okno: Baseline 1
Gait speed (m/s) will be measured using research-grade wearable sensors.
Baseline 1
Gait Speed
Časové okno: Baseline 2 (2-3 weeks after Baseline 1)
Gait speed (m/s) will be measured using research-grade wearable sensors.
Baseline 2 (2-3 weeks after Baseline 1)
Gait Speed
Časové okno: Immediately after the intervention (about 3 months)
Gait speed (m/s) will be measured using research-grade wearable sensors.
Immediately after the intervention (about 3 months)
Gait Speed
Časové okno: Follow-Up (about 1 month post-intervention)
Gait speed (m/s) will be measured using research-grade wearable sensors.
Follow-Up (about 1 month post-intervention)
Stride Length
Časové okno: Baseline 1
Quantified metrics of stride length (m) will be collected using research-grade wearable sensors.
Baseline 1
Stride Length
Časové okno: Baseline 2 (2-3 weeks after Baseline 1)
Quantified metrics of stride length (m) will be collected using research-grade wearable sensors.
Baseline 2 (2-3 weeks after Baseline 1)
Stride Length
Časové okno: Immediately after the intervention (about 3 months)
Quantified metrics of stride length (m) will be collected using research-grade wearable sensors.
Immediately after the intervention (about 3 months)
Stride Length
Časové okno: Follow-Up (about 1 month post-intervention)
Quantified metrics of stride length (m) will be collected using research-grade wearable sensors.
Follow-Up (about 1 month post-intervention)
Variability of Stride Time
Časové okno: Baseline 1
Stride-to-stride variability of stride time of the gait cycle will be measured using research-grade wearable sensors. Stride time variability is calculated by dividing the standard deviation of stride time by the mean of stride time, multiplied by 100 to express as a percentage.
Baseline 1
Variability of Stride Time
Časové okno: Baseline 2 (2-3 weeks after Baseline 1)
Stride-to-stride variability of stride time of the gait cycle will be measured using research-grade wearable sensors. Stride time variability is calculated by dividing the standard deviation of stride time by the mean of stride time, multiplied by 100 to express as a percentage.
Baseline 2 (2-3 weeks after Baseline 1)
Variability of Stride Time
Časové okno: Immediately after the intervention (about 3 months)
Stride-to-stride variability of stride time of the gait cycle will be measured using research-grade wearable sensors. Stride time variability is calculated by dividing the standard deviation of stride time by the mean of stride time, multiplied by 100 to express as a percentage.
Immediately after the intervention (about 3 months)
Variability of Stride Time
Časové okno: Follow-Up (about 1 month post-intervention)
Stride-to-stride variability of stride time of the gait cycle will be measured using research-grade wearable sensors. Stride time variability is calculated by dividing the standard deviation of stride time by the mean of stride time, multiplied by 100 to express as a percentage.
Follow-Up (about 1 month post-intervention)

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
10-Meter Walk Test (10MWT) - Comfortable Walking Speed
Časové okno: Baseline 1
This is a test of short-distance walking function. The participant will be asked to walk at comfortable walking speed (CWS) on a ten-meter straight walkway.
Baseline 1
10-Meter Walk Test (10MWT) - Comfortable Walking Speed
Časové okno: Baseline 2 (2-3 weeks after Baseline 1)
This is a test of short-distance walking function. The participant will be asked to walk at comfortable walking speed (CWS) on a ten-meter straight walkway.
Baseline 2 (2-3 weeks after Baseline 1)
10-Meter Walk Test (10MWT) - Comfortable Walking Speed
Časové okno: Immediately after the intervention (about 3 months)
This is a test of short-distance walking function. The participant will be asked to walk at comfortable walking speed (CWS) on a ten-meter straight walkway.
Immediately after the intervention (about 3 months)
10-Meter Walk Test (10MWT) - Comfortable Walking Speed
Časové okno: Follow-Up (about 1 month post-intervention)
This is a test of short-distance walking function. The participant will be asked to walk at comfortable walking speed (CWS) on a ten-meter straight walkway.
Follow-Up (about 1 month post-intervention)
10-Meter Walk Test (10MWT) - Fast Walking Speed
Časové okno: Baseline 1
This is a test of short-distance walking function. The participant will be asked to walk at fast walking speed (FWS) on a ten-meter straight walkway.
Baseline 1
10-Meter Walk Test (10MWT) - Fast Walking Speed
Časové okno: Baseline 2 (2-3 weeks after Baseline 1)
This is a test of short-distance walking function. The participant will be asked to walk at fast walking speed (FWS) on a ten-meter straight walkway.
Baseline 2 (2-3 weeks after Baseline 1)
10-Meter Walk Test (10MWT) - Fast Walking Speed
Časové okno: Immediately after the intervention (about 3 months)
This is a test of short-distance walking function. The participant will be asked to walk at fast walking speed (FWS) on a ten-meter straight walkway.
Immediately after the intervention (about 3 months)
10-Meter Walk Test (10MWT) - Fast Walking Speed
Časové okno: Follow-Up (about 1 month post-intervention)
This is a test of short-distance walking function. The participant will be asked to walk at fast walking speed (FWS) on a ten-meter straight walkway.
Follow-Up (about 1 month post-intervention)
Five Times Sit-to-Stand
Časové okno: Baseline 1
This test provides a method to quantify the time it takes for a person to stand up and sit down five times without using their hands.
Baseline 1
Five Times Sit-to-Stand
Časové okno: Baseline 2 (2-3 weeks after Baseline 1)
This test provides a method to quantify the time it takes for a person to stand up and sit down five times without using their hands.
Baseline 2 (2-3 weeks after Baseline 1)
Five Times Sit-to-Stand
Časové okno: Immediately after the intervention (about 3 months)
This test provides a method to quantify the time it takes for a person to stand up and sit down five times without using their hands.
Immediately after the intervention (about 3 months)
Five Times Sit-to-Stand
Časové okno: Follow-Up (about 1 month post-intervention)
This test provides a method to quantify the time it takes for a person to stand up and sit down five times without using their hands.
Follow-Up (about 1 month post-intervention)
Generic Walking Scale (Walk-12G)
Časové okno: Baseline 1
This test is a self-report questionnaire that measures everyday walking difficulties. Scores range from 12 to 60, with higher scores indicating greater perceived walking difficulties.
Baseline 1
Generic Walking Scale (Walk-12G)
Časové okno: Baseline 2 (2-3 weeks after Baseline 1)
This test is a self-report questionnaire that measures everyday walking difficulties. Scores range from 12 to 60, with higher scores indicating greater perceived walking difficulties.
Baseline 2 (2-3 weeks after Baseline 1)
Generic Walking Scale (Walk-12G)
Časové okno: Immediately after the intervention (about 3 months)
This test is a self-report questionnaire that measures everyday walking difficulties. Scores range from 12 to 60, with higher scores indicating greater perceived walking difficulties.
Immediately after the intervention (about 3 months)
Generic Walking Scale (Walk-12G)
Časové okno: Follow-Up (about 1 month post-intervention)
This test is a self-report questionnaire that measures everyday walking difficulties. Scores range from 12 to 60, with higher scores indicating greater perceived walking difficulties.
Follow-Up (about 1 month post-intervention)
Global Rating of Change (GROC) Scale
Časové okno: Immediately after the intervention (about 3 months)
This self-reported rating scale measures overall perceived improvement in areas related to amount of walking, intensity of walking, and walking capacity. Scores range from -7 to +7, with higher scores indicating greater improvement.
Immediately after the intervention (about 3 months)
Mini Balance Evaluation Systems Test (Mini-BESTest)
Časové okno: Baseline 1
This test is a clinical balance assessment tool designed to examine various elements of balance control. Scores range from 0 to 28, with higher scores indicating better balance.
Baseline 1
Mini Balance Evaluation Systems Test (Mini-BESTest)
Časové okno: Baseline 2 (2-3 weeks after Baseline 1)
This test is a clinical balance assessment tool designed to examine various elements of balance control. Scores range from 0 to 28, with higher scores indicating better balance.
Baseline 2 (2-3 weeks after Baseline 1)
Mini Balance Evaluation Systems Test (Mini-BESTest)
Časové okno: Immediately after the intervention (about 3 months)
This test is a clinical balance assessment tool designed to examine various elements of balance control. Scores range from 0 to 28, with higher scores indicating better balance.
Immediately after the intervention (about 3 months)
Mini Balance Evaluation Systems Test (Mini-BESTest)
Časové okno: Follow-Up (about 1 month post-intervention)
This test is a clinical balance assessment tool designed to examine various elements of balance control. Scores range from 0 to 28, with higher scores indicating better balance.
Follow-Up (about 1 month post-intervention)
Prefrontal Cortex Activity
Časové okno: Baseline 1
Prefrontal cortex activity (based on oxygenated hemoglobin) will be measured using Functional Near-Infrared Spectroscopy (fNIRS) during walking. This will be collected only for the cohort at Boston University.
Baseline 1
Prefrontal Cortex Activity
Časové okno: Baseline 2 (2-3 weeks after Baseline 1)
Prefrontal cortex activity (based on oxygenated hemoglobin) will be measured using Functional Near-Infrared Spectroscopy (fNIRS) during walking. This will be collected only for the cohort at Boston University.
Baseline 2 (2-3 weeks after Baseline 1)
Prefrontal Cortex Activity
Časové okno: Immediately after the intervention (about 3 months)
Prefrontal cortex activity (based on oxygenated hemoglobin) will be measured using Functional Near-Infrared Spectroscopy (fNIRS) during walking. This will be collected only for the cohort at Boston University.
Immediately after the intervention (about 3 months)
Dual-Task Cost on Gait Speed
Časové okno: Baseline 1
Dual-task cost is the difference between single-task walking and dual-task walking divided by single-task walking, multiplied by 100 to express as a percentage.
Baseline 1
Dual-Task Cost on Gait Speed
Časové okno: Baseline 2 (2-3 weeks after Baseline 1)
Dual-task cost is the difference between single-task walking and dual-task walking divided by single-task walking, multiplied by 100 to express as a percentage.
Baseline 2 (2-3 weeks after Baseline 1)
Dual-Task Cost on Gait Speed
Časové okno: Follow-Up (about 1 month post-intervention)
Dual-task cost is the difference between single-task walking and dual-task walking divided by single-task walking, multiplied by 100 to express as a percentage.
Follow-Up (about 1 month post-intervention)
Dual-Task Cost on Gait Speed
Časové okno: Immediately after the intervention (about 3 months)
Dual-task cost is the difference between single-task walking and dual-task walking divided by single-task walking, multiplied by 100 to express as a percentage.
Immediately after the intervention (about 3 months)
Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS Section I)
Časové okno: Baseline 1
The MDS-UPDRS is the most widely used clinical rating scale for Parkinson disease. Part I is an examination of non-motor experiences of daily living. Part IA is conducted by the rater, and Part IB is completed independently of the rater. Scores range from 0 to 52, with higher scores indicating greater impairment.
Baseline 1
Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS Section I)
Časové okno: Baseline 2 (2-3 weeks after Baseline 1)
The MDS-UPDRS is the most widely used clinical rating scale for Parkinson disease. Part I is an examination of non-motor experiences of daily living. Part IA is conducted by the rater, and Part IB is completed independently of the rater. Scores range from 0 to 52, with higher scores indicating greater impairment.
Baseline 2 (2-3 weeks after Baseline 1)
Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS Section I)
Časové okno: Immediately after the intervention (about 3 months)
The MDS-UPDRS is the most widely used clinical rating scale for Parkinson disease. Part I is an examination of non-motor experiences of daily living. Part IA is conducted by the rater, and Part IB is completed independently of the rater. Scores range from 0 to 52, with higher scores indicating greater impairment.
Immediately after the intervention (about 3 months)
Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS Section I)
Časové okno: Follow-Up (about 1 month post-intervention)
The MDS-UPDRS is the most widely used clinical rating scale for Parkinson disease. Part I is an examination of non-motor experiences of daily living. Part IA is conducted by the rater, and Part IB is completed independently of the rater. Scores range from 0 to 52, with higher scores indicating greater impairment.
Follow-Up (about 1 month post-intervention)
Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS Section II)
Časové okno: Baseline 1
The MDS-UPDRS is the most widely used clinical rating scale for Parkinson disease. Part II is a self-administered questionnaire to examine motor experiences of daily living. Scores range from 0 to 52, with higher scores indicating greater impairment.
Baseline 1
Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS Section II)
Časové okno: Baseline 2 (2-3 weeks after Baseline 1)
The MDS-UPDRS is the most widely used clinical rating scale for Parkinson disease. Part II is a self-administered questionnaire to examine motor experiences of daily living. Scores range from 0 to 52, with higher scores indicating greater impairment.
Baseline 2 (2-3 weeks after Baseline 1)
Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS Section II)
Časové okno: Follow-Up (about 1 month post-intervention)
The MDS-UPDRS is the most widely used clinical rating scale for Parkinson disease. Part II is a self-administered questionnaire to examine motor experiences of daily living. Scores range from 0 to 52, with higher scores indicating greater impairment.
Follow-Up (about 1 month post-intervention)
Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS Section II)
Časové okno: Immediately after the intervention (about 3 months)
The MDS-UPDRS is the most widely used clinical rating scale for Parkinson disease. Part II is a self-administered questionnaire to examine motor experiences of daily living. Scores range from 0 to 52, with higher scores indicating greater impairment.
Immediately after the intervention (about 3 months)
Movement Disorder Society Unified Parkinson Disease Rating Scale Motor Subsection (MDS-UPDRS Section III)
Časové okno: Baseline 1
The MDS-UPDRS is the most widely used clinical rating scale for Parkinson disease. Part III is a motor examination conducted by the rater. Scores range from 0 to 132, with higher scores indicating greater impairment.
Baseline 1
Movement Disorder Society Unified Parkinson Disease Rating Scale Motor Subsection (MDS-UPDRS Section III)
Časové okno: Baseline 2 (2-3 weeks after Baseline 1)
The MDS-UPDRS is the most widely used clinical rating scale for Parkinson disease. Part III is a motor examination conducted by the rater. Scores range from 0 to 132, with higher scores indicating greater impairment.
Baseline 2 (2-3 weeks after Baseline 1)
Movement Disorder Society Unified Parkinson Disease Rating Scale Motor Subsection (MDS-UPDRS Section III)
Časové okno: Immediately after the intervention (about 3 months)
The MDS-UPDRS is the most widely used clinical rating scale for Parkinson disease. Part III is a motor examination conducted by the rater. Scores range from 0 to 132, with higher scores indicating greater impairment.
Immediately after the intervention (about 3 months)
Movement Disorder Society Unified Parkinson Disease Rating Scale Motor Subsection (MDS-UPDRS Section III)
Časové okno: Follow-Up (about 1 month post-intervention)
The MDS-UPDRS is the most widely used clinical rating scale for Parkinson disease. Part III is a motor examination conducted by the rater. Scores range from 0 to 132, with higher scores indicating greater impairment.
Follow-Up (about 1 month post-intervention)
Variability of Stride Time During Walking with Digital Music Device
Časové okno: Baseline 1
Stride time variability will be measured during walking with digital music device during in-lab assessments. Stride-to-stride variability of stride time of the gait cycle will be measured using research-grade wearable sensors. Stride time variability is calculated by dividing the standard deviation of stride time by the mean of stride time, multiplied by 100 to express as a percentage.
Baseline 1
Variability of Stride Time During Walking with Digital Music Device
Časové okno: Baseline 2 (2-3 weeks after Baseline 1)
Stride time variability will be measured during walking with digital music device during in-lab assessments. Stride-to-stride variability of stride time of the gait cycle will be measured using research-grade wearable sensors. Stride time variability is calculated by dividing the standard deviation of stride time by the mean of stride time, multiplied by 100 to express as a percentage.
Baseline 2 (2-3 weeks after Baseline 1)
Variability of Stride Time During Walking with Digital Music Device
Časové okno: Immediately after the intervention (about 3 months)
Stride time variability will be measured during walking with digital music device during in-lab assessments. Stride-to-stride variability of stride time of the gait cycle will be measured using research-grade wearable sensors. Stride time variability is calculated by dividing the standard deviation of stride time by the mean of stride time, multiplied by 100 to express as a percentage.
Immediately after the intervention (about 3 months)
Variability of Stride Time During Walking with Digital Music Device
Časové okno: Follow-Up (about 1 month post-intervention)
Stride time variability will be measured during walking with digital music device during in-lab assessments. Stride-to-stride variability of stride time of the gait cycle will be measured using research-grade wearable sensors. Stride time variability is calculated by dividing the standard deviation of stride time by the mean of stride time, multiplied by 100 to express as a percentage.
Follow-Up (about 1 month post-intervention)
Speed During Walking with Digital Music Device
Časové okno: Baseline 1
Speed (m/s) will be measured during walking with digital music device during in-lab assessments.
Baseline 1
Speed During Walking with Digital Music Device
Časové okno: Baseline 2 (2-3 weeks after Baseline 1)
Speed (m/s) will be measured during walking with digital music device during in-lab assessments.
Baseline 2 (2-3 weeks after Baseline 1)
Speed During Walking with Digital Music Device
Časové okno: Immediately after the intervention (about 3 months)
Speed (m/s) will be measured during walking with digital music device during in-lab assessments.
Immediately after the intervention (about 3 months)
Speed During Walking with Digital Music Device
Časové okno: Follow-Up (about 1 month post-intervention)
Speed (m/s) will be measured during walking with digital music device during in-lab assessments.
Follow-Up (about 1 month post-intervention)
Stride Length During Walking with Digital Music Device
Časové okno: Baseline 1
Stride length (m) will be measured during walking with digital music device during in-lab assessments.
Baseline 1
Stride Length During Walking with Digital Music Device
Časové okno: Baseline 2 (2-3 weeks after Baseline 1)
Stride length (m) will be measured during walking with digital music device during in-lab assessments.
Baseline 2 (2-3 weeks after Baseline 1)
Stride Length During Walking with Digital Music Device
Časové okno: Immediately after the intervention (about 3 months)
Stride length (m) will be measured during walking with digital music device during in-lab assessments.
Immediately after the intervention (about 3 months)
Stride Length During Walking with Digital Music Device
Časové okno: Follow-Up (about 1 month post-intervention)
Stride length (m) will be measured during walking with digital music device during in-lab assessments.
Follow-Up (about 1 month post-intervention)
Parkinson's Disease Questionnaire-39 (PDQ-39)
Časové okno: Baseline 1
The PDQ-39 is a self-report questionnaire that assesses quality of life across 8 different dimensions. Items are scored based on a 5-point ordinal system with lower scores reflecting better quality of life (min = 0, max = 100).
Baseline 1
Parkinson's Disease Questionnaire-39 (PDQ-39)
Časové okno: Baseline 2 (2-3 weeks after Baseline 1)
The PDQ-39 is a self-report questionnaire that assesses quality of life across 8 different dimensions. Items are scored based on a 5-point ordinal system with lower scores reflecting better quality of life (min = 0, max = 100).
Baseline 2 (2-3 weeks after Baseline 1)
Parkinson's Disease Questionnaire-39 (PDQ-39)
Časové okno: Immediately after the intervention (about 3 months)
The PDQ-39 is a self-report questionnaire that assesses quality of life across 8 different dimensions. Items are scored based on a 5-point ordinal system with lower scores reflecting better quality of life (min = 0, max = 100).
Immediately after the intervention (about 3 months)
Parkinson's Disease Questionnaire-39 (PDQ-39)
Časové okno: Follow-Up (about 1 month post-intervention)
The PDQ-39 is a self-report questionnaire that assesses quality of life across 8 different dimensions. Items are scored based on a 5-point ordinal system with lower scores reflecting better quality of life (min = 0, max = 100).
Follow-Up (about 1 month post-intervention)
Self-Efficacy of Walking - Duration (SEW-D)
Časové okno: Baseline 1
The SEW-D is a self-report that will be administered to determine participants' beliefs of their physical capabilities to successfully complete incremental 5-minute intervals (5 to 40 minutes) of walking at a moderately fast pace, with responses made on 11-point Likert scale (0% = not at all confident; 100% = highly confident), with higher scores indicating higher confidence.
Baseline 1
Self-Efficacy of Walking - Duration (SEW-D)
Časové okno: Baseline 2 (2-3 weeks after Baseline 1)
The SEW-D is a self-report that will be administered to determine participants' beliefs of their physical capabilities to successfully complete incremental 5-minute intervals (5 to 40 minutes) of walking at a moderately fast pace, with responses made on 11-point Likert scale (0% = not at all confident; 100% = highly confident), with higher scores indicating higher confidence.
Baseline 2 (2-3 weeks after Baseline 1)
Self-Efficacy of Walking - Duration (SEW-D)
Časové okno: Immediately after the intervention (about 3 months)
The SEW-D is a self-report that will be administered to determine participants' beliefs of their physical capabilities to successfully complete incremental 5-minute intervals (5 to 40 minutes) of walking at a moderately fast pace, with responses made on 11-point Likert scale (0% = not at all confident; 100% = highly confident), with higher scores indicating higher confidence.
Immediately after the intervention (about 3 months)
Self-Efficacy of Walking - Duration (SEW-D)
Časové okno: Follow-Up (about 1 month post-intervention)
The SEW-D is a self-report that will be administered to determine participants' beliefs of their physical capabilities to successfully complete incremental 5-minute intervals (5 to 40 minutes) of walking at a moderately fast pace, with responses made on 11-point Likert scale (0% = not at all confident; 100% = highly confident), with higher scores indicating higher confidence.
Follow-Up (about 1 month post-intervention)
Activities-specific Balance Confidence (ABC)
Časové okno: Baseline 1
This test is a questionnaire that measures an individual's confidence (in percentage) that he/she will not lose balance or become unsteady while performing physical activities. The scores range from 0 to 100, with higher scores indicating greater confidence.
Baseline 1
Activities-specific Balance Confidence (ABC)
Časové okno: Baseline 2 (2-3 weeks after Baseline 1)
This test is a questionnaire that measures an individual's confidence (in percentage) that he/she will not lose balance or become unsteady while performing physical activities. The scores range from 0 to 100, with higher scores indicating greater confidence.
Baseline 2 (2-3 weeks after Baseline 1)
Activities-specific Balance Confidence (ABC)
Časové okno: Immediately after the intervention (about 3 months)
This test is a questionnaire that measures an individual's confidence (in percentage) that he/she will not lose balance or become unsteady while performing physical activities. The scores range from 0 to 100, with higher scores indicating greater confidence.
Immediately after the intervention (about 3 months)
Activities-specific Balance Confidence (ABC)
Časové okno: Follow-Up (about 1 month post-intervention)
This test is a questionnaire that measures an individual's confidence (in percentage) that he/she will not lose balance or become unsteady while performing physical activities. The scores range from 0 to 100, with higher scores indicating greater confidence.
Follow-Up (about 1 month post-intervention)
Trail-Making Test (TMT)
Časové okno: Baseline 1
This test measures the time it takes (seconds) to complete two visual-motor tasks. Higher scores indicate slower processing speed and greater cognitive impairment.
Baseline 1
Trail-Making Test (TMT)
Časové okno: Baseline 2 (2-3 weeks after Baseline 1)
This test measures the time it takes (seconds) to complete two visual-motor tasks. Higher scores indicate slower processing speed and greater cognitive impairment.
Baseline 2 (2-3 weeks after Baseline 1)
Trail-Making Test (TMT)
Časové okno: Immediately after the intervention (about 3 months)
This test measures the time it takes (seconds) to complete two visual-motor tasks. Higher scores indicate slower processing speed and greater cognitive impairment.
Immediately after the intervention (about 3 months)
Trail-Making Test (TMT)
Časové okno: Follow-Up (about 1 month post-intervention)
This test measures the time it takes (seconds) to complete two visual-motor tasks. Higher scores indicate slower processing speed and greater cognitive impairment.
Follow-Up (about 1 month post-intervention)
Montreal Cognitive Assessment (MoCA)
Časové okno: Baseline 1
The Montreal Cognitive Assessment (MoCA) is a brief screening tool designed to examine cognitive impairment. The score ranges from 0-30, with higher scores indicating less cognitive impairment.
Baseline 1
Montreal Cognitive Assessment (MoCA)
Časové okno: Baseline 2 (2-3 weeks after Baseline 1)
The Montreal Cognitive Assessment (MoCA) is a brief screening tool designed to examine cognitive impairment. The score ranges from 0-30, with higher scores indicating less cognitive impairment.
Baseline 2 (2-3 weeks after Baseline 1)
Montreal Cognitive Assessment (MoCA)
Časové okno: Immediately after the intervention (about 3 months)
The Montreal Cognitive Assessment (MoCA) is a brief screening tool designed to examine cognitive impairment. The score ranges from 0-30, with higher scores indicating less cognitive impairment.
Immediately after the intervention (about 3 months)
Montreal Cognitive Assessment (MoCA)
Časové okno: Follow-Up (about 1 month post-intervention)
The Montreal Cognitive Assessment (MoCA) is a brief screening tool designed to examine cognitive impairment. The score ranges from 0-30, with higher scores indicating less cognitive impairment.
Follow-Up (about 1 month post-intervention)
Variability of Stride Time During MMQ Walking Program with Digital Music Device
Časové okno: During training (about 3 months)
Stride time variability will be measured during the MMQ walking program with the digital music device. Stride-to-stride variability of stride time of the gait cycle will be measured using integrated sensors from the music device. Stride time variability is calculated by dividing the standard deviation of stride time by the mean of stride time, multiplied by 100 to express as a percentage.
During training (about 3 months)
Speed During MMQ Walking Program with Digital Music Device
Časové okno: During training (about 3 months)
Speed (m/s) will be measured during the MMQ walking program with the digital music device. Speed will be measured using integrated sensors from the music device.
During training (about 3 months)
Stride Length During MMQ Walking Program with Digital Music Device
Časové okno: During training (about 3 months)
Stride length (m) will be measured during the MMQ walking program with the digital music device. Stride length will be measured using integrated sensors from the music device.
During training (about 3 months)

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Boston University Charles River Campus

Spolupracovníci

Washington University School of Medicine
University of Utah
Michael J. Fox Foundation for Parkinson's Research

Vyšetřovatelé

  • Vrchní vyšetřovatel: Terry D. Ellis, PhD, PT, Boston University Center for Neurorehabilitation

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Obecné publikace

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

1. července 2026

Primární dokončení (Odhadovaný)

31. prosince 2028

Dokončení studie (Odhadovaný)

28. února 2029

Termíny zápisu do studia

První předloženo

6. července 2026

První předloženo, které splnilo kritéria kontroly kvality

13. července 2026

První zveřejněno (Aktuální)

15. července 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

15. července 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

13. července 2026

Naposledy ověřeno

1. července 2026

Více informací

Termíny související s touto studií

Klíčová slova

Další relevantní podmínky MeSH

Další identifikační čísla studie

  • 8547
  • 55213069 (Jiné číslo grantu/financování: Michael J. Fox Foundation)

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

ANO

Popis plánu IPD

De-identified data may be shared within reasonable request.

Časový rámec sdílení IPD

Beginning 3 months and ending 3 years after the publication of results

Kritéria přístupu pro sdílení IPD

Data relevant to eventual publication may be made available within reasonable request. Other datasets generated from the study may be accessed through requests in compliance with the study funder's protocol.

Typ podpůrných informací pro sdílení IPD

  • PROTOKOL STUDY
  • MÍZA
  • ICF

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ano

produkt vyrobený a vyvážený z USA

Ano

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Klinické studie na Parkinsonova nemoc (PD)

Prohledejte podobné pokusy

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

CROs by country

CROs in Costa Rica

Podmínky

Vzácné nemoci

Drogové intervence

Doplňky stravy

Sponzor / Spolupracovníci

Místa

Předplatit